| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9394 | Fulvestrant (Fresnius) | Fulvestrant (Fresnius) | 25mg | Hormonal Therapy | Estrogen Receptor Antagonist | No | 2019 | Dec 21, 2022 | In Use | |||
| J9027 | Clofarabine | Clolar | 1 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 2004 | Jan 1, 2006 | In Use | ||
| Q5171 | Denosumab (boncres) | Boncresa | 1mg | Ancillary Therapy | Monoclonal Antibody | RANKL | No | 2025 | Jun 17, 2026 | In Use | ||
| S9338 | Immunotherapy - non specific | Home infusion therapy, immunotherapy | NA | Immunotherapy | No | Jan 1, 2002 | In Use | |||||
| NA | Lorlatinib | Lorbrena | 25mg, 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Yes | 2018 | In Use | |||
| Q5165 | Denosumab-mobz | Oziltus | 1mg | Ancillary Therapy | Monoclonal Antibody | RANKL | No | 2025 | Jun 17, 2026 | In Use | ||
| NA | Selinexor | Xpovio | 20mg, 40mg, 50mg, 60mg | Chemotherapy | Enzyme Inhibitor | XPO1 | Yes | 2019 | In Use | |||
| J1094 | Dexamethasone Acetate | Dalalone DP, Decadron-LA | 1 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1978 | 2014 | Jan 1, 2003 | In Use | |
| J1952 | Leuprolide Mesylate | Camcevi | 1mg | Hormonal Therapy | GnRH Agonist | No | 2021 | Jan 26, 2022 | In Use | |||
| J9049 | Bortezomib (Hospira) | Bortezomib (Hospira) | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2022 | Dec 21, 2022 | In Use | ||
| NA | Bosutinib | Bosulif | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
| Q2017 | Teniposide | Teniposide | 50 mg | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | No | 1992 | Jul 1, 2000 | Jan 12, 2026 | In Use | |
| NA | Cyclophosphamide | Cyclophosphamide oral | 50 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1959 | In Use | |||
| J9208 | Ifosfamide | Ifosfamide | 1 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1988 | Jan 1, 1999 | In Use | ||
| S0088 | Imatinib mesylate | Gleevec | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2001 | Jan 1, 2002 | In Use | ||
| NA | Imatinib mesylate | Gleevec | 400 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2001 | In Use | |||
| J9324 | Pemetrexed disodium | Pemrydi-rtu | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2023 | Dec 7, 2023 | In Use | ||
| J9323 | Pemetrexed ditromethamine | Pemetrexed ditromethamine | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Jul 11, 2023 | In Use | ||
| NA | Alpelisib | Piqray | 200mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2019 | In Use | |||
| NA | Uridine Triacetate | Xuriden | 2 g | Ancillary Therapy | Chemoprotective | Antidote | Yes | 2015 | In Use | |||
| J9320 | Streptozocin | Zanosar | 1 g | Chemotherapy | Alkylating Agent | Nitrosourea | No | 1982 | Jan 1, 1986 | In Use | ||
| C9492 | Durvalumab | Imfinzi | 10 mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2017 | Oct 1, 2017 | In Use | ||
| J9360 | Vinblastine | Oncovin, Vincasar PFS | 1 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1965 | Jan 1, 1986 | In Use | ||
| C9476 | Daratumumab | Darzalex | 10 mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2015 | Jul 1, 2016 | In Use | ||
| J9395 | Fulvestrant | Faslodex | 25 mg | Hormonal Therapy | Estrogen Receptor Antagonist | No | 2002 | Jan 1, 2004 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home